Kazia Therapeutics (KZIA) news
Recent news
Kazia Therapeutics - Files for offering of 95,110 American depositary shares representing 47,555,000 ordinary shares - SEC filing
Kazia Therapeutics Limited (NASDAQ: KZIA) has announced the pricing of a registered public offering, which includes the issuance of 2,580,000 American Depositary Shares (ADSs), each representing 500 ordinary shares of the company, or pre-funded warrants to purchase ADSs in lieu of ADSs for certain…
AInvest Wire · 5h agoKazia Therapeutics Limited announces pricing of up to $120 million public offering
AInvest Wire · 3d agoKazia Therapeutics Limited announces proposed public offering
AInvest Wire · 3d agoKazia Therapeutics - Phase 1B study enrollment expected to complete by July 2027, with interim clinical updates anticipated throughout 2026 and 2027
AInvest Wire · 3d agoKazia Therapeutics Ltd: BTIG initiates coverage with buy rating; price target $34
Kazia Therapeutics Ltd (NASDAQ: KZIA) has recently attracted attention from analysts, with BTIG initiating coverage on the stock with a "Buy" rating and a price target of $34. This move follows a series of developments that have bolstered investor confidence in the biotechnology firm. Kazia’s lead…
AInvest Wire · Jul 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.